BioSpace News Archive

Patients, clinicians and families facing uncertainty about their choices for managing Type 2 diabetes and rare diseases will gain new evidence to inform their decision making from comparative clinical effectiveness research (CER) studies that the Patient-Centered Outcomes Research Institute (PCORI) Board of Governors today approved for a total of $42.7 million in new funding.

Testing remains an important cornerstone of our nation’s fight against COVID-19.

Camber Spine, a leading innovator in spine and medical technologies, has announced the national rollout of a complete set of devices and tools required to perform the Oblique Lateral Interbody Fusion Surgery (OLIF) technique.

CytoSorbents Corporation (NASDAQ: CTSO) announces the filing of an Investigational Device Exemption (IDE) application to conduct the clinical study, “Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T),” in the United States to support an initial FDA regulatory approval.

Biodesix, Inc. (NASDAQ: BDSX) a leading data-driven diagnostic solutions company with a focus in lung disease, today announced financial and operating results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update.

Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, provided a business update for the fourth quarter and full year 2020.

Berkeley Lights, Inc. (Nasdaq: BLI), a leader in Digital Cell Biology, today announced the company will be participating in the upcoming KeyBanc Life Sciences & MedTech Investor Forum. Berkeley Lights’ management is scheduled to participate in a fireside chat on Wednesday, March 24 at 7:45 a.m. Pacific Time / 10:45 a.m. Eastern Time.

Surgalign Holdings, Inc., a global medical technology company focused on advancing spine surgery and improving patient outcomes, including through the application of digital technology, reported operating results for the fourth quarter and full year 2020.

Prometheus Biosciences, Inc. (Nasdaq: RXDX), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory bowel disease (IBD), today announced the closing of its initial public offering

Sandoz Inc. today announced the in-licensing of commercial distribution rights to the brand and authorized generic of respiratory inhalation medicine Proventil® HFA (albuterol sulfate) Inhalation Aerosol from Kindeva Drug Delivery, a global contract development and manufacturing organization supplying the product.